683 Capital Management’s Forte Biosciences FBRX Stock Holding History

683 Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$518K	–	182
2026 Q1	$518K	Sell	20,000 -20,000	-50%	-$576K	0.03%	181
2025 Q4	$1.09M	Buy	+40,000	New	+$701K	0.05%	131
2021 Q1	–	Sell	-1,825	Closed	-$1.66M	–	198
2020 Q4	$1.66M	Buy	+1,825	New	+$1.72M	0.08%	105
2019 Q3	–	Sell	-1,000	Closed	-$2.5M	–	157
2019 Q2	$2.5M	Hold	1,000	–	–	0.23%	76
2019 Q1	$4.08M	Hold	1,000	–	–	0.37%	56
2018 Q4	$3.08M	Buy	1,000 +867	+652%	+$3.73M	0.19%	75
2018 Q3	$780K	Hold	133	–	–	0.05%	103
2018 Q2	$467K	Buy	+133	New	+$487K	0.03%	112

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

683 Capital Management's FBRX Position: Q2 2026 in Review

683 Capital Management sold out of Forte Biosciences (FBRX) in Q2 2026, closing a stake of 20,000 shares — an estimated $518K sold.

683 Capital Management first reported a position in FBRX in Q2 2018 and held it in 8 quarters. The position peaked at $4.08M in Q1 2019. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

683 Capital Management reported no remaining Forte Biosciences position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 20,000 Forte Biosciences shares in Q2 2026, an estimated $518K.
683 Capital Management first reported a position in Forte Biosciences in Q2 2018 and held it in 8 quarters.
683 Capital Management's Forte Biosciences position peaked at $4.08M in Q1 2019.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.